Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome
2018年3月23日 更新者:Suresh Mathews、Auburn University
Alterations in Phosphorylated Fetuin-A, a Novel Regulator of Insulin Action in Insulin Resistance and Metabolic Syndrome: Effects of Lifestyle Modification
Fetuin-A has been identified as a novel physiological regulator of insulin action in vitro, in intact cells and in vivo in animals.
Previous research has shown that circulating levels of fetuin-A were increased in animal models of insulin resistance and diabetes.
Additionally, several human investigation studies demonstrate a correlation of fetuin-A levels with body mass index, insulin resistance, and a fatty liver.
Recently, the investigators have elucidated the role of fetuin-A phosphorylation in the regulation of insulin action, demonstrating that phosphorylation is critical for the inhibitory activity of fetuin-A.
The objectives of this study are twofold: (1) Quantitate phosphorylated fetuin-A levels in individuals with insulin resistance and metabolic syndrome, and (2) Investigate the effects of lifestyle modifications (acute or chronic exercise and dietary modifications) on fetuin-A phosphorylation and insulin sensitivity.
研究概览
详细说明
There are several objectives of this study: (1) Quantitate phosphorylated fetuin-A levels and the daily variation in these levels in individuals with insulin resistance and metabolic syndrome; (2) Investigate the short-term responses of fetuin-A phosphorylation and changes in insulin resistance that occur with a single session of aerobic exercise; (3) Characterize and compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification, and; (4) Investigate the influence of weight loss on the short-term responses of fetuin-A phosphorylation and changes in insulin resistance that occur with a single session of aerobic exercise.
Our hypothesis is that phosphofetuin-A levels are tightly correlated with insulin resistance and that lifestyle modifications will improve insulin sensitivity and decrease phosphorylated fetuin-A levels.
研究类型
介入性
注册 (实际的)
42
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Alabama
-
Auburn、Alabama、美国、36849
- Auburn University
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
30年 至 65年 (成人、年长者)
接受健康志愿者
是的
有资格学习的性别
男性
描述
Inclusion Criteria:
- 30 to 65 years of age
- obese (BMI > 30 kg⋅m2 or % fat > 30, and waist girth > 88 cm)
- weight stable over the previous 6 months
Exclusion Criteria:
- smoker
- documented cardiovascular or metabolic disease
- currently taking medication to alter lipid or glucose metabolism
- practicing regular leisure physical activity over the previous 6 months
- engaged in strenuous vocational activity over the previous 6 months
- signs or symptoms of latent heart disease
- conditions that would preclude treadmill walking
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Obese individuals
Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited.
Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
|
Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Total plasma fetuin-A and phosphorylated fetuin-A
大体时间:Total fetuin-A and phosphorylated fetuin-A levels will be measured once every 4 weeks until participant achieves a targeted weight-loss goal of 8-10%. It is anticipated that most participants will achieve their weight-loss goal within 6-10 months.
|
Measure total fetuin-A and phosphorylated fetuin-A levels in plasma
|
Total fetuin-A and phosphorylated fetuin-A levels will be measured once every 4 weeks until participant achieves a targeted weight-loss goal of 8-10%. It is anticipated that most participants will achieve their weight-loss goal within 6-10 months.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Suresh Mathews, PhD、Auburn University
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2007年10月10日
初级完成 (实际的)
2015年5月31日
研究完成 (实际的)
2015年5月31日
研究注册日期
首次提交
2018年3月19日
首先提交符合 QC 标准的
2018年3月23日
首次发布 (实际的)
2018年3月27日
研究记录更新
最后更新发布 (实际的)
2018年3月27日
上次提交的符合 QC 标准的更新
2018年3月23日
最后验证
2018年3月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Weight loss的临床试验
-
The Miriam HospitalNational Institute on Minority Health and Health Disparities (NIMHD)尚未招聘